Johnson & Johnson Stock (NYSE:JNJ)
Previous Close
$186.93
52W Range
$140.68 - $194.48
50D Avg
$182.96
200D Avg
$164.34
Market Cap
$449.57B
Avg Vol (3M)
$8.53M
Beta
0.39
Div Yield
$5.08 (2.72%)
JNJ Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
JNJ Performance
Latest News
Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson
Oct 28, 25 | 6:15 PM | globenewswire.comJ&J Stock Can Fall
Oct 28, 25 | 9:25 AM | forbes.comTexas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
Oct 28, 25 | 9:13 AM | reuters.comHere's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Oct 27, 25 | 10:50 AM | zacks.comJNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
Oct 27, 25 | 10:21 AM | zacks.comI have invested in dividends for 25 years—These stocks prove long-term dividend investing works
Oct 24, 25 | 11:29 AM | 247wallst.comSmart Acquisitions And Profit Margin Growth Amid Strategic Repositioning
Oct 24, 25 | 4:30 AM | seekingalpha.comI have invested in dividends for 20 years. These stocks are my top dividend compounders of all time
Oct 23, 25 | 11:26 AM | 247wallst.comJohnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference
Oct 22, 25 | 4:36 PM | businesswire.comJohnson & Johnson Stock To $134?
Oct 22, 25 | 2:00 PM | forbes.comJohnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Oct 22, 25 | 10:00 AM | zacks.comJohnson & Johnson Draws Long-Term Buyers as Markets Turn Cautious
Oct 21, 25 | 4:49 PM | fool.comJohnson & Johnson Targets Accelerated Growth Across Segments in 2026
Oct 21, 25 | 10:17 AM | zacks.comGoldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
Oct 20, 25 | 11:16 AM | 247wallst.comJohnson & Johnson's M&A Strategy Is the Real Story for Investors
Oct 18, 25 | 12:04 PM | marketbeat.comShould You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
Oct 17, 25 | 1:15 PM | zacks.comS&P 500 Gains and Losses Today: Regional Banks Slump on Worries About Bad Loans; Data Storage Stocks Surge
Oct 16, 25 | 5:45 PM | investopedia.comJ&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
Oct 16, 25 | 2:06 PM | zacks.comTry Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools